{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:06:51Z","timestamp":1777446411801,"version":"3.51.4"},"reference-count":80,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":74,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2001,10,30]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>1. Evidence from recent experimental and clinical studies suggests that excessive circulating levels of aldosterone can bring about adverse cardiovascular sequelae independent of the effects on blood pressure. Examples of these sequelae are the development of myocardial and vascular fibrosis in uninephrectomized, salt\u2010loaded rats infused with mineralocorticoids and, in humans, an association of aldosterone with left ventricular hypertrophy, impaired diastolic and systolic function, salt and water retention causing aggravation of congestion in patients with established congestive cardiac failure (CCF), reduced vascular compliance and an increased risk of arrhythmias (resulting from intracardiac fibrosis, hypokalaemia, hypomagnesaemia, reduced baroreceptor sensitivity and potentiation of catecholamine effects).<\/jats:p><jats:p>2. These sequelae of aldosterone excess may contribute to the pathogenesis and worsen the prognosis of CCF and hypertension.<\/jats:p><jats:p>3. The heart and blood vessels may be capable of extra\u2010adrenal aldosterone biosynthesis, raising the possibility that aldosterone may have paracrine or autocrine (and not just endocrine) effects on cardiovascular tissues.<\/jats:p><jats:p>4. The high prevalence of CCF, which is associated with secondary aldosteronism, and primary aldosteronism (PAL; recently recognized to be a much more common cause of hypertension than was previously thought) argue for an important role for aldosterone excess as a cause of cardiovascular injury.<\/jats:p><jats:p>5. The recognition of non\u2010blood pressure\u2010dependent adverse sequelae of aldosterone excess raises the question as to whether normotensive individuals with PAL, who have been detected as a result of genetic or biochemical screening among families with inherited forms of PAL, are at excess risk of cardiovascular events.<\/jats:p><jats:p>6. Provided that patients are carefully investigated in order to permit the appropriate selection of specific surgical (laparoscopic adrenalectomy for PAL that lateralizes on adrenal venous sampling) or medical (treatment with aldosterone antagonist medications) management and safety considerations for the use of aldosterone antagonists are kept in mind, the appreciation of a widening role for aldosterone in cardiovascular disease should provide a substantially better outlook for many patients with CCF and hypertension.<\/jats:p>","DOI":"10.1046\/j.1440-1681.2001.03523.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T11:07:54Z","timestamp":1047380874000},"page":"783-791","source":"Crossref","is-referenced-by-count":51,"title":["New Perspectives On The Role Of Aldosterone Excess In Cardiovascular Disease"],"prefix":"10.1111","volume":"28","author":[{"given":"Michael","family":"Stowasser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02158515"},{"key":"e_1_2_11_3_2","first-page":"6","article-title":"Primary aldosteronism, a new clinical syndrome.","volume":"45","author":"Conn JW.","year":"1955","journal-title":"J. Lab. Clin. Med."},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1964.03070160046009"},{"key":"e_1_2_11_5_2","unstructured":"BiglieriEG&KaterCE.Disorders of the adrenal cortex. In: Stein JH (ed.).Internal Medicine 3rd edn. Little Brown Boston. 1991; 2188\u2013207."},{"key":"e_1_2_11_6_2","unstructured":"KaplanNM.Clinical Hypertension 6th edn. Williams & Wilkins Baltimore. 1994; 389\u2013408."},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1964.03070160037008"},{"key":"e_1_2_11_8_2","unstructured":"LaraghJH.Renovascular hypertension: A paradigm for all hypertension.J. Hypertens.1986;4(Suppl. 1): S79\u201388."},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197203022860901"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00196-X"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)90952-W"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.83.6.1849"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117269"},{"key":"e_1_2_11_15_2","first-page":"E657","article-title":"Determinants of cardiac fibrosis in experimental hypermineralocorticoid states.","volume":"269","author":"Young M","year":"1995","journal-title":"Am. J. Physiol."},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.26.6.971"},{"key":"e_1_2_11_17_2","unstructured":"DelcayreC CailmailS GarnierA TataraE MorineauG SwynghedauwB.Prevention of myocardial fibrosis by eplerenone. In:Proceedings of the 26th International Aldosterone Conference.19\u201320 June 2000 Toronto. Meetings & Events International Communications Toronto. 2000; 40 (Abstract)."},{"key":"e_1_2_11_18_2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/ajh\/6.6.487","article-title":"Myocardial fibrosis in the rat with mineralocorticoid excess: Prevention of scarring by amiloride.","volume":"6","author":"Campbell SE","year":"1993","journal-title":"Am. J. Hypertens."},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1987.tb02422.x"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.2.175"},{"key":"e_1_2_11_21_2","doi-asserted-by":"crossref","unstructured":"BrillaCG MaischB ZhouG WeberKT.Hormonal regulation of cardiac fibroblast function.Eur. Heart. J.1995;16(Suppl. C): 45\u201350.","DOI":"10.1093\/eurheartj\/16.suppl_C.45"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/28.12.1863"},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.33.4.981"},{"key":"e_1_2_11_24_2","unstructured":"FullertonMJ&FunderJW.Aldosterone regulates collagen output of rat cardiac fibroblasts by upregulation of endothelin receptors.Endocrin. Soc. Proc.1998;93: 511 (Abstract)."},{"key":"e_1_2_11_25_2","unstructured":"BrownNJ FogoAB VaughanDE.Aldosterone modulates plasminogen activator inhibitor\u20101 expression in vitro and in vivo. In:Proceedings of the 26th International Aldosterone Conference.19\u201320 June 2000 Toronto. Meetings & Events International Communications Toronto. 2000; 36 (Abstract)."},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(97)00097-7"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.17.6.1152"},{"key":"e_1_2_11_28_2","unstructured":"DorranceAM WebbRC GrekinR.Aldosterone antagonism reduces cerebral infarct size and epidermal growth factor receptor expression. In:Proceedings of the 26th International Aldosterone Conference.19\u201020 June 2000 Toronto. Meetings & Events International Communications Toronto. 2000; 33 (Abstract)."},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.9.4883"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.20.2694"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.25.2.170"},{"key":"e_1_2_11_32_2","doi-asserted-by":"crossref","first-page":"24 316","DOI":"10.1016\/S0021-9258(19)51084-5","article-title":"Vascular aldosterone: Biosynthesis and a link to angiotensin II\u2010induced hypertrophy of vascular smooth muscle cells.","volume":"269","author":"Hatakeyama H","year":"1994","journal-title":"J. Biol. Chem."},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.138.8.3369"},{"key":"e_1_2_11_34_2","doi-asserted-by":"crossref","unstructured":"MacKenzieSM ClarkCJ IngramMCet al.Corticosteroid production by fetal rat hippocampal neurons.Endocr. Res.2000;26: 531\u20135.","DOI":"10.3109\/07435800009048566"},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0039-128x(94)00004-v"},{"key":"e_1_2_11_36_2","first-page":"443","article-title":"Mineralocorticoid receptor blockade in chronic heart failure.","volume":"9","author":"Struthers AD.","year":"1995","journal-title":"J. Hum. Hypertens."},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.19.3.270"},{"key":"e_1_2_11_38_2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1042\/cs0950687","article-title":"Aldosterone blunts the baroreflex response in man.","volume":"95","author":"Yee KM","year":"1998","journal-title":"Clin. Sci."},{"key":"e_1_2_11_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(82)90441-6"},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.82.5.1730"},{"key":"e_1_2_11_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(97)00091-6"},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80686-9"},{"key":"e_1_2_11_43_2","doi-asserted-by":"crossref","unstructured":"RamiresFJA MansurA CoelhoOet al.Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or ischemic cardiomyopathy.Am. J. Cardiol.2000;85: 1207\u201311.","DOI":"10.1016\/S0002-9149(00)00729-3"},{"key":"e_1_2_11_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90241-4"},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90242-5"},{"key":"e_1_2_11_46_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_2_11_47_2","doi-asserted-by":"crossref","unstructured":"ZannadF AllaF DoussetB PerezA PittB.Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Insights from the Randomized Aldactone Evaluation Study (RALES).Circulation2000;102: 2700\u20136.","DOI":"10.1161\/01.CIR.102.22.2700"},{"key":"e_1_2_11_48_2","doi-asserted-by":"crossref","unstructured":"StruthersAD.Aldosterone escape during ACE inhibitor therapy in chronic heart failure.Eur. Heart J.1995;16(Suppl. N): 103\u20136.","DOI":"10.1093\/eurheartj\/16.suppl_N.103"},{"key":"e_1_2_11_49_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.25.4.602"},{"key":"e_1_2_11_50_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.77.1.24"},{"key":"e_1_2_11_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90240-D"},{"key":"e_1_2_11_52_2","unstructured":"Navarro\u2010LopezF CocaA PareJCet al.Left ventricular hypertrophy in asymptomatic essential hypertension: Its relationship with aldosterone and the increase in sodium\u2013proton exchanger activity.Eur. Heart J.1993;14(Suppl. J): 38\u201341."},{"key":"e_1_2_11_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000590"},{"key":"e_1_2_11_54_2","doi-asserted-by":"crossref","unstructured":"SchlaichMP SchobelHP HilgersK SchmiederRE.Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects.Am. J. Cardiol.2000;85: 1199\u20131206.","DOI":"10.1016\/S0002-9149(00)00728-1"},{"key":"e_1_2_11_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00301-4"},{"key":"e_1_2_11_56_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.6.569"},{"key":"e_1_2_11_57_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.22.2213"},{"key":"e_1_2_11_58_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.33.2.703"},{"key":"e_1_2_11_59_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.95.6.1471"},{"key":"e_1_2_11_60_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.27.5.1039"},{"key":"e_1_2_11_61_2","doi-asserted-by":"crossref","unstructured":"AbeM HamadaM MatsuokaH ShigematsuY SumimotoT HiwadaK.Myocardial scintigraphic characteristics in patients with primary aldosteronism.Hypertension1994;23(Suppl. I): I\u2010164\u20137.","DOI":"10.1161\/01.HYP.23.1_Suppl.I164"},{"key":"e_1_2_11_62_2","first-page":"212","article-title":"Evidence of exercise\u2010induced myocardial ischemia in patients with primary aldosteronism: The Cross\u2010sectional Primary Aldosteronism and Heart Italian Multicenter Study.","volume":"47","author":"Napoli C","year":"1999","journal-title":"J. Invest. Med."},{"key":"e_1_2_11_63_2","doi-asserted-by":"crossref","unstructured":"GordonRD StowasserM TunnyTJ KlemmSA RutherfordJC.High incidence of primary aldosteronism in 199 patients referred with hypertension.Clin. Exp. Pharmacol. Physiol.1994;21: 315\u201318.","DOI":"10.1111\/j.1440-1681.1994.tb02519.x"},{"key":"e_1_2_11_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1993.tb01687.x"},{"key":"e_1_2_11_65_2","unstructured":"GordonRD StowasserM KlemmSA TunnyTJ.Primary aldosteronism and other forms of mineralocorticoid hypertension. In: Swales JD (ed.).Textbook of Hypertension. Blackwell Science London. 1994; Ch. 47."},{"key":"e_1_2_11_66_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019616-199707040-00003"},{"key":"e_1_2_11_67_2","doi-asserted-by":"crossref","unstructured":"LimPO RodgersP CardaleK WatsonAD MacDonaldTM.Potentially high prevalence of primary aldosteronism in a primary\u2010care population.Lancet1999;353: 40.","DOI":"10.1016\/S0140-6736(05)74868-6"},{"key":"e_1_2_11_68_2","unstructured":"RaynerBL OpieLH DavidsonJS.The aldosterone\/renin ratio as a screening test for primary aldosteronism.S. Afr. Med. J.2000;90: 394\u2013400."},{"key":"e_1_2_11_69_2","doi-asserted-by":"crossref","unstructured":"FardellaCE MossoL Gomez\u2010SanchezCEet al.Primary aldosteronism in essential hypertensives: Prevalence biochemical profile and molecular biology.J. Clin. Endocrinol. Metab.2000;85: 1863\u20137.","DOI":"10.1210\/jc.85.5.1863"},{"key":"e_1_2_11_70_2","doi-asserted-by":"crossref","unstructured":"LohKC KoayES KhawMC EmmanuelSC YoungJrWF.Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore.J. Clin. Endocrinol. Metab.2000;85: 2854\u20139.","DOI":"10.1210\/jc.85.8.2854"},{"key":"e_1_2_11_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/355262a0"},{"key":"e_1_2_11_72_2","doi-asserted-by":"crossref","unstructured":"StowasserM&GordonRD.Primary aldosteronism: Learning from the study of familial varieties.J. Hypertens.2000;18: 1165\u201376.","DOI":"10.1097\/00004872-200018090-00002"},{"key":"e_1_2_11_73_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.1225"},{"key":"e_1_2_11_74_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.11.4031"},{"key":"e_1_2_11_75_2","doi-asserted-by":"crossref","unstructured":"StowasserM BachmannAW HuggardPJ RossettiTR GordonRD.Severity of hypertension in familial hyperaldosteronism type I. Relationship to gender and to degree of biochemical disturbance.J. Clin. Endocrinol. Metab.2000;85: 2160\u20136.","DOI":"10.1210\/jc.85.6.2160"},{"key":"e_1_2_11_76_2","doi-asserted-by":"crossref","unstructured":"FalloF VeglioF MulateroPet al.Genetic studies in familial aldosteronism not suppressible by dexamethasone.J. Endocr. Genet.2000;1: 159\u201364.","DOI":"10.1515\/IJDHD.2000.1.3.159"},{"key":"e_1_2_11_77_2","doi-asserted-by":"crossref","unstructured":"LaffertyAR TorpyDJ StowasserMet al.A novel locus for low\u2010renin hypertension: Familial hyperaldosteronism type II maps to chromosome 7 (7p22).J. Med. Genet.2000;37: 831\u20135.","DOI":"10.1136\/jmg.37.11.831"},{"key":"e_1_2_11_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/nsb0197-32"},{"key":"e_1_2_11_79_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1991.tb01446.x"},{"key":"e_1_2_11_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1043-2760(98)00058-7"},{"key":"e_1_2_11_81_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411009"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1440-1681.2001.03523.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1440-1681.2001.03523.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T05:59:31Z","timestamp":1697522371000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1440-1681.2001.03523.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,30]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,10,30]]}},"alternative-id":["10.1046\/j.1440-1681.2001.03523.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1440-1681.2001.03523.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10,30]]}}}